Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.69 |
| ▸ | MMP2 | P08253 | 11/20 | 0.35 |
| ▸ | MMP3 | P08254 | 8/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | STAT6 | P42226 | 2/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6671059 | 1.00 | TUBB1 (0.69) | TUBB1MMP2MMP3CNR1CNR2 | |
| SCHEMBL22069870 | 1.00 | TUBB1 (0.69) | TUBB1MMP2MMP3CNR1CNR2 | |
| SCHEMBL30779234 | 1.00 | TUBB1 (0.69) | TUBB1MMP2MMP3CNR1CNR2 | |
| SCHEMBL6671035 | 1.00 | TUBB1 (0.69) | TUBB1MMP2MMP3CNR1CNR2 | |
| SCHEMBL6670834 | 0.92 | TUBB1 (0.78) | TUBB1MMP2MMP3CNR1CNR2 | |
| Taltobulin SCHEMBL4378011 | 0.92 | TUBB1 (0.81) | TUBB1MMP2MMP3STAT6MMP1 | |
| Taltobulin SCHEMBL58356 | 0.92 | TUBB1 (0.81) | TUBB1MMP2MMP3STAT6MMP1 | |
| Taltobulin SCHEMBL13848320 | 0.92 | TUBB1 (0.81) | TUBB1MMP2MMP3STAT6MMP1 | |
| Taltobulin SCHEMBL13660106 | 0.92 | TUBB1 (0.81) | TUBB1MMP2MMP3STAT6MMP1 | |
| Taltobulin SCHEMBL6670481 | 0.92 | TUBB1 (0.81) | TUBB1MMP2MMP3STAT6MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SHBG, CYP11A1, CYP11B1 | TUBB1 1472/4885MMP2 4185/4885MMP3 4369/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885MMP2 2746/4885MMP3 1124/4885 |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885MMP2 2746/4885MMP3 1124/4885 |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | FCGRT, QARS1, INHA | TUBB1 436/4885MMP2 4036/4885MMP3 4424/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | TUBB1 436/4885MMP2 4036/4885MMP3 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.